Cipla invests additional 3 million dollars in US Chase Pharmaceuticals
New Delhi : Drug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer's disease.
The company in May 2014 had invested USD 1.5 million to acquire 14.6 per cent stake in Chase Pharmaceuticals.
"Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company...made an additional investment of USD 3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase," Cipla said in a BSE filing.
Consequently, Cipla UK's total investment in Chase would aggregate to approximately USD 5.12 million for a 16.7 per cent stake on a fully diluted basis.
As per the agreement in May, Cipla had said it will make an additional USD 4.5 million investment in Chase upon achievement of certain milestones in this direction.
The investment done through Cipla (EU) Ltd, UK, was part of USD 21 million syndicate to finance Phase 2a and Phase 2b clinical trials for Chase's lead drug CPC 201 for treating the disease.
Other investors in the syndicate were Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.
The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.
The company in May 2014 had invested USD 1.5 million to acquire 14.6 per cent stake in Chase Pharmaceuticals.
"Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company...made an additional investment of USD 3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase," Cipla said in a BSE filing.
Consequently, Cipla UK's total investment in Chase would aggregate to approximately USD 5.12 million for a 16.7 per cent stake on a fully diluted basis.
As per the agreement in May, Cipla had said it will make an additional USD 4.5 million investment in Chase upon achievement of certain milestones in this direction.
The investment done through Cipla (EU) Ltd, UK, was part of USD 21 million syndicate to finance Phase 2a and Phase 2b clinical trials for Chase's lead drug CPC 201 for treating the disease.
Other investors in the syndicate were Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.
The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd